Zobrazeno 1 - 10
of 8 032
pro vyhledávání: '"PI3Kδ"'
Autor:
Jia, Wenqing1,2 (AUTHOR) chengxianchao@aliyun.com, Liu, Jingdian1 (AUTHOR) 15698043683@163.com, Cheng, Xianchao2 (AUTHOR), Li, Xingguo3 (AUTHOR) xingguoli@neau.edu.cn, Ma, Yukui1,4 (AUTHOR) xingguoli@neau.edu.cn
Publikováno v:
International Journal of Molecular Sciences. Oct2024, Vol. 25 Issue 20, p11250. 17p.
Autor:
Xiao Yang, Huichen Bai, Xi Yuan, Xiaolong Yang, Ye Liu, Mingming Guo, Nan Hu, Beibei Jiang, Zeqin Lian, Zhilong Ma, Jingyuan Wang, Xuebing Sun, Taichang Zhang, Dan Su, Yue Wu, Jing Li, Fan Wang, Zhiwei Wang, Lai Wang, Xuesong Liu, Xiaomin Song
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 57, Iss , Pp 101053- (2024)
PI3Kδ is a key signal transduction molecule in normal and malignant B cells, as well as in T-regulatory cells, making it a promising target for treatment of hematologic malignancies through both direct killing and anti-tumor immunity regulation. BGB
Externí odkaz:
https://doaj.org/article/6e9ecf70bc114685b74062abcfc58de0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lougaris, Vassilios1 (AUTHOR), Piane, Federico Le2 (AUTHOR), Cancrini, Caterina3,4 (AUTHOR), Conti, Francesca5 (AUTHOR), Tommasini, Alberto6,7 (AUTHOR), Badolato, Raffaele8 (AUTHOR), Trizzino, Antonino9 (AUTHOR), Zecca, Marco10 (AUTHOR), De Rosa, Antonio11 (AUTHOR), Barzaghi, Federica12 (AUTHOR), Pignata, Claudio11 (AUTHOR) pignata@unina.it
Publikováno v:
Italian Journal of Pediatrics. 5/20/2024, Vol. 50 Issue 1, p1-11. 11p.
Autor:
Vassilios Lougaris, Federico Le Piane, Caterina Cancrini, Francesca Conti, Alberto Tommasini, Raffaele Badolato, Antonino Trizzino, Marco Zecca, Antonio De Rosa, Federica Barzaghi, Claudio Pignata
Publikováno v:
Italian Journal of Pediatrics, Vol 50, Iss 1, Pp 1-11 (2024)
Abstract Activated phosphoinositide 3-kinase (PI3Kδ) Syndrome (APDS) is an inborn error of immunity (IEI) with a variable clinical presentation, characterized by infection susceptibility and immune dysregulation that may overlaps with other Primary
Externí odkaz:
https://doaj.org/article/c3a720bfdd824b72a325d875a42d7813
Autor:
Shuwen Jiang, Xiangkun Li, Weifang Xue, Sumei Xia, Jian Wang, Yang Sai, Guangxiu Dai, Weiguo Su
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Amdizalisib, also named HMPL-689, a novel selective and potent PI3Kδ inhibitor, is currently under Phase II clinical development in China for treating hematological malignancies. The preclinical pharmacokinetics (PK) of amdizalisib were extensively
Externí odkaz:
https://doaj.org/article/171a0dd993234a97b37b3479bb05b230
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rao, V. Koneti, Kulm, Elaine, Grossman, Jennifer, Buchbinder, David, Chong, Hey, Bradt, Jason, Webster, Sharon, Šedivá, Anna, Dalm, Virgil A., Uzel, Gulbu
Publikováno v:
In Blood Advances 25 June 2024 8(12):3092-3108
Autor:
Zimmerman, Jessica A. O.1,2 (AUTHOR) jessica-zimmerman@uiowa.edu, Fang, Mimi2,3 (AUTHOR), Pufall, Miles A.2,3 (AUTHOR) mpufall@uiowa.edu
Publikováno v:
Cancers. Jan2024, Vol. 16 Issue 1, p143. 16p.
Autor:
Ya-nan Zheng, Si-yue Lou, Jun Lu, Fan-li Zheng, Yong-mei Tang, En-jun Zhang, Sun-liang Cui, Hua-jun Zhao
Publikováno v:
Cell Death and Disease, Vol 15, Iss 7, Pp 1-10 (2024)
Abstract Colorectal cancer (CRC) is one of the most common tumors of the digestive system worldwide. KRAS mutations limit the use of anti-EGFR antibodies in combination with chemotherapy for the treatment of CRC. Therefore, novel targeted therapies a
Externí odkaz:
https://doaj.org/article/ddab4cd7abc444498aeb851f953fcb51